Literature DB >> 3438787

Ceftriaxone for treatment of uncomplicated gonorrhea: routine use of a single 125-mg dose in a sexually transmitted disease clinic.

H H Handsfield1, E W Hook.   

Abstract

We retrospectively analyzed the efficacy of ceftriaxone in a single dose of 125 mg given intramuscularly for treatment of uncomplicated gonorrhea. Neisseria gonorrhoeae was eradicated from 152 (99%) of 154 patients who returned for test-of-cure, including all 83 heterosexual men and women and 69 (97%) of 71 homosexual men. Cure was achieved for 109 (99%) of 110 urethral or cervical infections, 52 (98%) of 53 rectal infections, and 15 of 15 pharyngeal infections. All infected sites were cured in 58 additional patients treated with ceftriaxone (125 mg) plus tetracycline (500 mg four times daily for seven days). These results confirm those of earlier clinical trials showing that 125 mg of ceftriaxone is effective therapy for uncomplicated gonorrhea in a geographic area with a high prevalence of gonococci with chromosomally mediated antibiotic resistance.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3438787

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  4 in total

Review 1.  Drug therapies for sexually transmitted diseases. Clinical and economic considerations.

Authors:  W R Bowie
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

2.  Susceptibility of Neisseria gonorrhoeae associated with pelvic inflammatory disease to cefoxitin, ceftriaxone, clindamycin, gentamicin, doxycycline, azithromycin, and other antimicrobial agents.

Authors:  R J Rice; J S Knapp
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

3.  Antimicrobial susceptibilities of Neisseria gonorrhoeae strains representing five distinct resistance phenotypes.

Authors:  R J Rice; J S Knapp
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

4.  Trends in susceptibility of Neisseria gonorrhoeae to ceftriaxone from 1985 through 1991.

Authors:  J R Schwebke; W Whittington; R J Rice; H H Handsfield; J Hale; K K Holmes
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.